A compound of Formula I ##STR20## wherein: A is (CH.sub.2).sub.n where n is 1-6; R.sub.1 is C.sub.1-4 alkyl; phenyl; substituted phenyl where the phenyl substituents are independently selected from one or more of the group consisting of C.sub.1-5 alkyl, C.sub.1-5 alkoxy and halogen; phenylC.sub.1-5 alkyl; or substituted phenylC.sub.1-5 alkyl where the phenyl substituents are independently selected from one or more of the group consisting of C.sub.1-5 alkyl, C.sub.1-5 alkoxy and halogen; R.sub.2 is hydrogen, C.sub.1-6 alkyl, C.sub.2-5 alkenyl, C.sub.2-5 alkynyl, phenylC.sub.1-5 alkyl, or substituted phenylC.sub.1-5 alkyl where the phenyl substituents are independently selected from one or more of the group consisting of C.sub.1-5 alkyl, C.sub.1-5 alkoxy and halogen; E is ##STR21## where: m is 1-5; R.sub.3 is hydrogen, C.sub.1-6 alkyl or oxygen, where if R.sub.3 is oxygen, the dashed line represents a bond and if R.sub.3 is C.sub.1-6 alkyl the dashed line is absent; R.sub.4 is oxygen, hydrogen, C.sub.1-5 alkyl, formyl, carboxy, C.sub.1-5 alkylcarbonyl, C.sub.1-5 alkoxycarbonyl, phenylC.sub.1-5 alkoxy, substituted phenylC.sub.1-5 alkoxy where the phenyl substituents are independently selected from one or more of the group consisting of C.sub.1-5 alkyl, C.sub.1-5 alkoxy and halogen, carbamoyl and substitued carbamoyl where the nitrogen substituents are independently selected from one or more of the groups consisting of hydrogen C.sub.1-5 alkyl, C.sub.1-5 alkoxy and hydroxy, where if R.sub.4 is oxygen, the dashed line represents a bond and if R.sub.4 is any other substituent, the dashed line is absent; R.sub.5 is hydrogen, C.sub.1-5 alkyl or taken together with R.sub.6 to form a cyclohexane, cyclopentane or cyclopropane ring; R.sub.6 is hydrogen, C.sub.1-5 alkyl or taken together with R.sub.5 to form a cyclohexane, cyclopentane or cyclopropane ring; or pharmaceutically acceptable salts thereof.
›2.↳ 1The compounds of claim 1 where R.sub.1 is C.sub.1-6 alkyl, n is 2-4, and R.sub.2 is hydrogen, C.sub.1-6 alkyl, or C.sub.2-6 alkenyl.d2+10
The compounds of claim 1 where R.sub.1 is C.sub.1-6 alkyl, n is 2-4, and R.sub.2 is hydrogen, C.sub.1-6 alkyl, or C.sub.2-6 alkenyl.
›3.↳ 2The compounds of claim 2 ##STR22##d3
The compounds of claim 2 ##STR22##
›4.↳ 2The compounds of claim 2 where R.sub.3 is oxygen and R.sub.4 is hydrogen, C.sub.1-5 alkoxycarbonyl, or oxygen.d3+8
The compounds of claim 2 where R.sub.3 is oxygen and R.sub.4 is hydrogen, C.sub.1-5 alkoxycarbonyl, or oxygen.
›5.↳ 4The compounds of claim 4 where R.sub.4 is hydrogen and E is ##STR23##d4+7
The compounds of claim 4 where R.sub.4 is hydrogen and E is ##STR23##
›6.↳ 5The compounds of claim 5 where m is 2 to 5.d5+6
The compounds of claim 5 where m is 2 to 5.
›8.↳ 6A pharmaceutical composition comprising a compound according to claim 6 and a pharmaceutically acceptable carrier or diluent.d6+1
A pharmaceutical composition comprising a compound according to claim 6 and a pharmaceutically acceptable carrier or diluent.
›11.↳ 8A method of treating benign prostatic hyperplasia comprising administering an effective dose of a compound of claim 8 to a patient.d7
A method of treating benign prostatic hyperplasia comprising administering an effective dose of a compound of claim 8 to a patient.
›9.↳ 6multiple · 1, 6A method of treating benign prostatic hyperplasia comprising administering an effective dose of a compound of claim 1 or claim 6 to a patient.d6+2
Multiple dependency — claims 1, 6. Shown here under 6; it stands on every one of them.
A method of treating benign prostatic hyperplasia comprising administering an effective dose of a compound of claim 1 or claim 6 to a patient.
›12.↳ 9The method of claim 9 where the effective dose is 0.05-1.0 mg/kg daily.d7
The method of claim 9 where the effective dose is 0.05-1.0 mg/kg daily.
›13.↳ 9The method of claim 9 where the compound is administered orally and an effective dose is 0.01-100 mg/kg daily.d7
The method of claim 9 where the compound is administered orally and an effective dose is 0.01-100 mg/kg daily.
›10.↳ 6A method of treating benign prostatic hyperplasia comprising administering an effective dose of a compound of claim 6 to a patient.d6
A method of treating benign prostatic hyperplasia comprising administering an effective dose of a compound of claim 6 to a patient.
›7.↳ 1A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.d2
A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.
